Conserved features of cancer cells define their sensitivity to HAMLET-induced death; C-Myc and glycolysis

Oncogene

Volumn 30, Issue 48, 2011, Pages 4765-4779

  Storm, P ^a   Aits, S ^a   Puthia, M K ^b   Urbano, A ^b   Northen, T ^c   Powers, S ^d   Bowen, B ^c   Chao, Y ^b   Reindl, W ^c   Lee, D Y ^c   Sullivan, N L ^d   Zhang, J ^d   Trulsson, M ^a   Yang, H ^b   Watson, J D ^d   Svanborg, C ^a  

^a LUND UNIVERSITY   (Sweden)

^b AGENCY FOR SCIENCE   (Singapore)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^d Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

Author keywords

c Myc; Glycolysis; HAMLET; Metabolism

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; ALPHA LACTALBUMIN; FRUCTOSE 2,6 BIPHOSPHATASE 1; HEXOKINASE 1; HYPOXIA INDUCIBLE FACTOR 1; MYC PROTEIN; PHOSPHATASE; PROTEIN HAMLET; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL DEATH; CELL METABOLISM; CONTROLLED STUDY; ENZYME ACTIVITY; GENETIC IDENTIFICATION; GLYCOLYSIS; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING;

CELL DEATH; CELL LINE, TUMOR; GLYCOLYSIS; HUMANS; LACTALBUMIN; MICROSCOPY, CONFOCAL; OLEIC ACIDS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 82455188049     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.196     Document Type: Article

References (52)

1. Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V. (2008). Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: mapping the site of binding. J Biol Chem 283: 13482-13490.
2. Balendiran GK, Dabur R, Fraser D. (2004). The role of glutathione in cancer. Cell Biochem Funct 22: 343-352. (Pubitemid 39518098)
3. Baran R, Reindl W, Northen TR. (2009). Mass spectrometry based metabolomics and enzymatic assays for functional genomics. Curr Opin Microbiol 12: 547-552.
4. Brest P, Gustafsson M, Mossberg AK, Gustafsson L, Duringer C, Hamiche A et al. (2007). Histone deacetylase inhibitors promote the tumoricidal effect of HAMLET. Cancer Res 67: 11327-11334. (Pubitemid 350248559)
5. Brummelkamp TR, Bernards R. (2003). New tools for functional mammalian cancer genetics. Nat Rev Cancer 3: 781-789. (Pubitemid 37328816)
6. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233. (Pubitemid 351380249)
7. Coleman MC, Asbury CR, Daniels D, Du J, Aykin-Burns N, Smith BJ et al. (2008). 2-Deoxy-D-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer. Free Radic Biol Med 44: 322-331.
8. Dang CV. (1999). c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19: 1-11. (Pubitemid 29018404)
9. Dang CV, Kim JW, Gao P, Yustein J. (2008). The interplay between MYC and HIF in cancer. Nat Rev Cancer 8: 51-56.
10. Dang CV, Le A, Gao P. (2009). MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15: 6479-6483.
11. Denko NC. (2008). Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8: 705-713.
12. Duringer C, Hamiche A, Gustafsson L, Kimura H, Svanborg C. (2003). HAMLET interacts with histones and chromatin in tumor cell nuclei. J Biol Chem 278: 42131-42135. (Pubitemid 37310480)
13. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M et al. (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
14. Felsher DW, Bishop JM. (1999). Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4: 199-207. (Pubitemid 29456888)
15. Fiehn O, Wohlgemuth G, Scholz M. (2005). Setup and annotation of metabolomic experiments by integrating biological and mass spectrometric metadata. Lect Notes Comput Sci 3615: 224-239. (Pubitemid 41420593)
16. Fischer W, Gustafsson L, Mossberg AK, Gronli J, Mork S, Bjerkvig R et al. (2004). Human alpha-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res 64: 2105-2112. (Pubitemid 38339460)
17. Gustafsson L, Leijonhufvud I, Aronsson A, Mossberg AK, Svanborg C. (2004). Treatment of skin papillomas with topical alphalactalbumin-oleic acid. N Engl J Med 350: 2663-2672.
18. Hakansson A, Zhivotovsky B, Orrenius S, Sabharwal H, Svanborg C. (1995). Apoptosis induced by a human milk protein. Proc Natl Acad Sci USA 92: 8064-8068.
19. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell 100: 57-70. (Pubitemid 30046295)
20. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
21. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T et al. (2008). Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 123: 476-483. (Pubitemid 351842036)
22. Hsu PP, Sabatini DM. (2008). Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
23. Ihrlund LS, Hernlund E, Khan O, Shoshan MC. (2008). 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol 2: 94-101.
24. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3: 177-185.
25. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS et al. (2004). Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324: 269-275. (Pubitemid 39311489)
26. Kroemer G, Pouyssegur J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482. (Pubitemid 351766797)
27. Li Y, Holland CA, Hartley JW, Hopkins N. (1984). Viral integration near c-myc in 10-20% of mcf 247-induced AKR lymphomas. Proc Natl Acad Sci USA 81: 6808-6811. (Pubitemid 15221010)
28. Mathupala SP, Rempel A, Pedersen PL. (1997). Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr 29: 339-343.
29. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. (2005). Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308. (Pubitemid 41058775)
30. Mossberg AK, Hou Y, SvenssonM, Holmqvist B, Svanborg C. (2010). HAMLET treatment delays bladder cancer development. J Urol 183: 1590-1597.
31. Mossberg AK, Wullt B, Gustafsson L, Mansson W, Ljunggren E, Svanborg C. (2007). Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int J Cancer 121: 1352-1359. (Pubitemid 47293805)
32. Nilsson JA, Cleveland JL. (2003). Myc pathways provoking cell suicide and cancer. Oncogene 22: 9007-9021. (Pubitemid 38121701)
33. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 3: 187-197.
34. Pelengaris S, Khan M, Evan GI. (2002). Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 109: 321-334. (Pubitemid 34606875)
35. Satoh J, Nanri Y, Yamamura T. (2006). Rapid identification of 14-3-3-binding proteins by protein microarray analysis. J Neurosci Methods 152: 278-288. (Pubitemid 43343500)
36. Scholz M, Fiehn O. (2007). SetupX-a public study design database for metabolomic projects. Pac Symp Biocomput, 169-180.
37. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA et al. (1997). c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94: 6658-6663. (Pubitemid 27281920)
38. Silva JM, Li MZ, Chang K, Ge W, Golding MC, Rickles RJ et al. (2005). Second-generation shRNA libraries covering the mouse and human genomes. Nat Genet 37: 1281-1288. (Pubitemid 41568714)
39. Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR et al. (2008). Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 319: 617-620. (Pubitemid 351197063)
40. Smyth GK, Speed T. (2003). Normalization of cDNA microarray data. Methods 31: 265-273. (Pubitemid 37338763)
41. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM et al. (2008). Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
42. Svanborg C, Agerstam H, Aronson A, Bjerkvig R, Duringer C, FischerW et al. (2003). HAMLET kills tumor cells by an apoptosislike mechanism-cellular, molecular, and therapeutic aspects. Adv Cancer Res 88: 1-29. (Pubitemid 36343277)
43. Svensson M, Hakansson A, Mossberg AK, Linse S, Svanborg C. (2000). Conversion of alpha-lactalbumin to a protein inducing apoptosis. Proc Natl Acad Sci USA 97: 4221-4226. (Pubitemid 30226114)
44. Thomas DB, Lingwood CA. (1975). A model of cell cycle control: effects of thymidine on synchronous cell cultures. Cell 5: 37-42.
45. Vander Heiden MG, Cantley LC, Thompson CB. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
46. Warburg O. (1956). On the origin of cancer cells. Science 123: 309-314.
47. Watson PH, Pon RT, Shiu RP. (1991). Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51: 3996-4000.
48. Weinstein IB, Joe A. (2008). Oncogene addiction. Cancer Res 68: 3077-3080; discussion 3080.
49. Wilson JE. (2003). Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206: 2049-2057. (Pubitemid 36761808)
50. Yalcin A, Telang S, Clem B, Chesney J. (2009). Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 86: 174-179.
51. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B et al. (2008). An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135: 852-864.
52. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI et al. (2007). HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11: 407-420. (Pubitemid 46670080)